Form 4: Control Empresarial de Capitales S.A. de C.V. Acquires Additional ProKidney Corp. Shares

Control Empresarial de Capitales S.A. de C.V. purchased 100,000 Class A Ordinary Shares of ProKidney Corp. at an average price of $0.7482 per share.

Summary

• Control Empresarial de Capitales S.A. de C.V. acquired 100,000 Class A Ordinary Shares of ProKidney Corp. on April 16, 2025.
• The shares were purchased at a weighted average price of $0.7482, with individual prices ranging from $0.7472 to $0.75.
• Following the transaction, Control Empresarial beneficially owns 73,430,330 shares, including Class A and Class B Ordinary Shares.
• The Slim Family, as beneficiaries of a Mexican trust that owns Control Empresarial, may be deemed to indirectly beneficially own these shares.
• Control Empresarial owns 10,311,685 Class A Ordinary Shares and 63,118,645 Class B Ordinary Shares.
• These shares represent approximately 25.1% of the total shares issued and outstanding, which is 292,697,649 shares as of March 17, 2025.
• The Slim Family may also be deemed to beneficially own approximately 25.1% of the total shares issued and outstanding.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. The purchase of shares by a major shareholder is generally a positive sign, but the document lacks specific details about the company's performance or future plans.

Positives

• Increased investment by a major shareholder, Control Empresarial, could signal confidence in ProKidney Corp.'s future prospects.

Future Outlook

The document does not contain specific forward-looking statements regarding ProKidney Corp.'s future performance, but it does mention earnout rights that vest based on the achievement of certain share price milestones.

Industry Context

This filing indicates continued investment by a significant shareholder, which is a common occurrence in the biotech industry as companies progress through clinical trials and regulatory approvals. Monitoring similar filings from other major shareholders can provide insights into overall investor sentiment.

Comparison to Industry Standards

• Comparing the ownership stake of the Slim Family (25.1%) to other major shareholders in similar biotech companies can provide context.
• For example, institutional ownership in companies like CRISPR Therapeutics or Beam Therapeutics often ranges from 50% to 80%, indicating a higher level of institutional support.
• The earnout structure tied to share price milestones is also a common practice in biotech mergers and acquisitions, aligning the interests of the acquired company's shareholders with the acquirer's.

Stakeholder Impact

• The increased investment by Control Empresarial could positively impact shareholder confidence.
• The earnout provisions could incentivize management to achieve the share price milestones, benefiting shareholders.

Key Dates

Keywords

ProKidney Corp, Control Empresarial, Slim Family, Class A Ordinary Shares, Class B Ordinary Shares, Beneficial Ownership, Share Purchase, SEC Form 4